Wegovy® and Mounjaro® are both self injection GLP-1 treatments that are used once a week. Wegovy® has the active ingredient semaglutide, whereas Mounjaro has the active ingredient tirzepatide.
Mounjaro® is the more effective treatment and studies have shown patients to achieve up to 20% weight loss on the highest doses. This is versus the 15% average of Wegovy® and 7.5% average for Ozempic® which is solely indicated for type 2 diabetes